{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:36:20Z","timestamp":1789054580781,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jjcc.2019.12.010","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:43:35Z","timestamp":1579653815000},"page":"606-613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Advent of New perioperative care for fluid management after cardiovascular surgery: A review of current evidence"],"prefix":"10.1016","volume":"75","author":[{"given":"Hiroyuki","family":"Nishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2019.12.010_bib0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/0267659109105079","article-title":"Cardiopulmonary bypass and edema: physiology and pathophysiology","volume":"23","author":"Hirleman","year":"2008","journal-title":"Perfusion"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1191\/0267659104pf723oa","article-title":"Highly positive intraoperative fluid balance during cardiac surgery is associated with adverse outcome","volume":"19","author":"Toraman","year":"2004","journal-title":"Perfusion"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/icvts\/ivs208","article-title":"Does perioperative furosemide usage reduce the need for renal replacement therapy in cardiac surgery patients?","volume":"15","author":"Gandhi","year":"2012","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0020","first-page":"287","article-title":"High volumes of intravenous fluid during cardiac surgery are associated with increased mortality","volume":"2","author":"Pradeep","year":"2010","journal-title":"HSR Proc Intensive Care Cardiovasc Anesth"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00392-014-0754-7","article-title":"Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study","volume":"104","author":"Simopoulos","year":"2015","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0003-4975(99)01298-9","article-title":"Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery","volume":"69","author":"Sirivella","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0035","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jacc.2011.03.056","volume":"58","author":"Sezai","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0040","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/eurheartj\/ehu484","article-title":"Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies","volume":"36","author":"Anker","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0045","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jacc.2006.10.048","article-title":"Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial","volume":"49","author":"Mentzer","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0050","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1152\/ajprenal.00119.2002","article-title":"Loop diuretics: from the Na-K-2Cl transporter to clinical use","volume":"284","author":"Shankar","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0055","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5527\/wjn.v4.i2.196","article-title":"Renal dopaminergic system: pathophysiological implications and clinical perspectives","volume":"4","author":"Choi","year":"2015","journal-title":"World J Nephrol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0060","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","article-title":"Combination of loop diuretics with thiazide-type diuretics in heart failure","volume":"56","author":"Jentzer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jjcc.2015.09.011","article-title":"Natriuretic peptides for perioperative management of cardiac surgery","volume":"67","author":"Sezai","year":"2016","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0070","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0075","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1210\/en.2004-1590","article-title":"Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia","volume":"146","author":"Miyazaki","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0080","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0085","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","article-title":"Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction","volume":"22","author":"Matsue","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0090","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jjcc.2012.09.002","article-title":"Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure","volume":"60","author":"Watanabe","year":"2012","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0100","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1253\/circj.CJ-16-1122","article-title":"Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction- prospective randomized controlled study","volume":"81","author":"Tamaki","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0105","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(24)35289-9","article-title":"Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats","volume":"292","author":"Hirano","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.jjcc.2019.12.010_bib0110","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1007\/s10557-011-6350-4","article-title":"Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure","volume":"25","author":"Onogawa","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.jjcc.2019.12.010_bib0115","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0120","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jcph.197","article-title":"Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide","volume":"53","author":"Suzuki","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","article-title":"Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment- results from the K-STAR Study","volume":"82","author":"Inomata","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0130","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0135","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial","volume":"52","author":"Udelson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0140","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s10157-016-1379-0","article-title":"Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure","volume":"21","author":"Katsumata","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0145","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1253\/circj.CJ-14-0126","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload","volume":"78","author":"Kinugawa","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0150","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1253\/circj.CJ-14-0592","article-title":"Novel diuretic strategies for the treatment of heart failure in Japan","volume":"78","author":"Dohi","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0155","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jjcc.2018.02.006","article-title":"Comparison of two dosing methods for immediate administration of tolvaptan in acute decompensated heart failure","volume":"72","author":"Oguri","year":"2018","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2012.08.020","article-title":"Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population","volume":"61","author":"Matsue","year":"2013","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ahj.2010.05.032","article-title":"Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization","volume":"160","author":"Abdel-Qadir","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0175","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1253\/circj.CJ-15-0928","article-title":"Predictors of worsening renal function in patients with acute decompensated heart failure treated by low-dose carperitide","volume":"80","author":"Kawase","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0180","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s00595-015-1251-y","article-title":"Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial","volume":"45","author":"Nishi","year":"2015","journal-title":"Surg Today"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0185","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1536\/ihj.15-483","article-title":"A Safety and efficacy study of tolvaptan following open heart surgery in 109 cases","volume":"57","author":"Kono","year":"2016","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0190","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1532\/hsf.1470","article-title":"Efficacy of tolvaptan in patients with volume overload after cardiac surgery","volume":"18","author":"Noguchi","year":"2015","journal-title":"Heart Surg Forum"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0195","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2016.06.156","article-title":"Effects of short-term administration of tolvaptan after open heart surgery","volume":"220","author":"Matsuyama","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0200","first-page":"111","article-title":"Efficacy and safety evaluation of tolvaptan on management of fluid balance after cardiovascular surgery using cardiopulmonary bypass","volume":"62","author":"Suehiro","year":"2016","journal-title":"Osaka City Med J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0205","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1053\/j.jvca.2016.06.013","article-title":"Efficacy of tolvaptan on fluid management after cardiovascular surgery using cardiopulmonary bypass","volume":"30","author":"Ito","year":"2016","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0210","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1253\/circj.CJ-17-0967","article-title":"Can tolvaptan protect renal function in the early postoperative period of cardiac surgery?- results of a single-center randomized controlled study","volume":"82","author":"Kishimoto","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0215","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12872-016-0341-0","article-title":"The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery","volume":"16","author":"Kato","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0220","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00595-016-1406-5","article-title":"The efficacy of tolvaptan in the perioperative management of chronic kidney disease patients undergoing open-heart surgery","volume":"47","author":"Yamada","year":"2017","journal-title":"Surg Today"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0225","first-page":"331","article-title":"Relationship between heart failure treatment and development of worsening renal function among hospitalized patients","volume":"147","author":"Butler","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0230","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","article-title":"Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?","volume":"2","author":"Felker","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0235","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1536\/ihj.53.313","article-title":"Long-term prognostic impact after acute kidney injury in patients with acute heart failure","volume":"53","author":"Shirakabe","year":"2012","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0240","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0245","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00380-018-1270-x","article-title":"Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR","volume":"34","author":"Ikeda","year":"2019","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0250","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13019-015-0372-0","article-title":"Early introduction of tolvaptan after cardiac surgery: a renal sparing strategy in the light of the renal resistive index measured by ultrasound","volume":"10","author":"Kato","year":"2015","journal-title":"J Cardiothorac Surg"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0255","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","article-title":"Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients","volume":"77","author":"Imamura","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0260","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1253\/circj.CJ-14-0244","article-title":"Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure","volume":"78","author":"Imamura","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0265","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11748-016-0712-6","article-title":"Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery","volume":"65","author":"Kido","year":"2017","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0270","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40256-018-0304-1","article-title":"Short-term effects of tolvaptan in tricuspid insufficiency combined with left heart valve replacement-caused volume-overload patients: results of a prospective pilot study","volume":"19","author":"Yuan","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0275","doi-asserted-by":"crossref","first-page":"e0570","DOI":"10.1097\/MD.0000000000010570","article-title":"Tolvaptan rescue contrast-induced acute kidney injury: A case report","volume":"97","author":"Lee","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jjcc.2019.12.010_bib0280","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jjcc.2018.10.003","article-title":"Update of acute and long-term tolvaptan therapy","volume":"73","author":"Imamura","year":"2018","journal-title":"J Cardiol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508720300022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508720300022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:02:29Z","timestamp":1760274149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508720300022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0914508720300022"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.12.010","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advent of New perioperative care for fluid management after cardiovascular surgery: A review of current evidence","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}